Inflammation of the gastrointestinal tract can be debilitating. Photo: Pixabay Results from the anonymous online survey, published in the journal Crohns & Colitis, examined IBD severity, medication adherence, quality of life, as well as medicinal cannabis use and its perceived impact on these measures. The survey expanded on previous surveys by accessing a larger patient population. Continue reading →

While the role of the gut microbiota is well-established in the pathogenesis of gastrointestinal disorders such as irritable bowel syndrome and ulcerative colitis, an accumulating body of research implicates its involvement in the development of various neurodegenerative diseases.1,2 The strongest evidence thus far pertains to multiple sclerosis (MS), Parkinson disease (PD), and autism spectrum disorder (ASD). Emerging findings also point the potential for altered microbial composition playing a role in the development of Alzheimer disease, stroke, and amyotrophic lateral sclerosis.2 It is becoming clear that a healthy diverse microbiome is essential for brain health, especially as we age, said John F Cryan, PhD, professor and chair of the Department of Anatomy and Neuroscience at the University of College Cork in Cork, Ireland, and co-author of a review published in February 2020 in the Lancet Neurology.2 It has been proposed that the microbiota-gut-brain axis represents a bidirectional communication pathway through which the gut microbiota can influence the central nervous system, contributing to neurological and behavioral alterations. Continue reading →

TOKYO --Takeda Pharmaceuticalplans to sell its over-the-counter medicine business, looking to reduce a massive debt load after last year's purchase of Irish drugmaker Shire and tighten its focus on advanced treatments, Nikkei learned Friday. Japan's biggest drug company is talking with financial institutions to choose a potential buyer for wholly owned subsidiary Takeda Consumer Healthcare, aiming to sell for around 400 billion yen ($3.71 billion). Continue reading →

Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in blood This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, United Kingdom, April 24, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Plc plc (Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it pursuant to an asset purchase agreement it has acquired all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin D (Act D; a.k.a Continue reading →